Solid Biosciences (SLDB) Current Deferred Revenue (2020 - 2022)

Solid Biosciences (SLDB) has 3 years of Current Deferred Revenue data on file, last reported at $6.2 million in Q1 2022.

• For the quarter ending Q1 2022, Current Deferred Revenue fell 65.07% year-over-year to $6.2 million; the trailing twelve-month figure through Mar 2022 stood at $6.2 million (down 65.07% YoY), and the FY2021 full-year result was $8.1 million, down 61.0% from the prior year.
• Current Deferred Revenue retreated to $6.2 million in Q1 2022, from $8.1 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $20.7 million in Q4 2020 to a low of $6.2 million in Q1 2022.
• A 3-year average of $12.6 million and a median of $11.6 million in 2021 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue tumbled 61.0% in 2021 and slumped 65.07% in 2022, its largest moves.
• Tracing SLDB's Current Deferred Revenue over 3 years: stood at $20.7 million in 2020, then plunged by 61.0% to $8.1 million in 2021, then fell by 23.64% to $6.2 million in 2022.
• Business Quant data shows SLDB's Current Deferred Revenue at $6.2 million in Q1 2022, $8.1 million in Q4 2021, and $8.9 million in Q3 2021.